Degarelix Versus Goserelin Plus Bicalutamide in the Short‐Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis

ConclusionAn early, significant and clinically more pronounced improvement of LUTS, especially in patients with moderate‐to‐severe LUTS or advanced PCa, was seen with degarelix vs. goserelin plus bicalutamide.
Source: LUTS: Lower Urinary Tract Symptoms - Category: Urology & Nephrology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

PROSTATE cancer is the most common cancer in men in the UK and it usually develops slowly, so there may be no signs for many years. Advanced prostate cancer means the cancer has spread to other parts of the body, and experiencing pain in different areas of the body may signal the cancer has spread.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Night-shift work has been shown to be associated with breast cancer risk. Might it also play a role in prostate cancer development?American Journal of Epidemiology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Authors: Anttinen M PMID: 31701789 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
This study was registered with Japan Registry of Clinical Trials (jRCTs052190026). PMID: 31701044 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Contemp Clin Trials Commun Source Type: research
Conclusion: LDR-EBRT may provide more effective PSA control at 5 years compared with HDR-EBRT. Direct comparison of these treatments through randomised trials are recommended to investigate this hypothesis further. PMID: 31701035 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Radiat Oncol Source Type: research
AbstractPurpose of ReviewThe purpose of this review is to explore the role of monocyte chemoattractant protein-1 (MCP-1 or CCL2) in the processes that underpin bone remodelling, particularly the action of osteoblasts and osteoclasts, and its role in the development and metastasis of cancers that target the bone.Recent FindingsMCP-1 is a key mediator of osteoclastogenesis, being the highest induced gene during intermittent treatment with parathyroid hormone (iPTH), but also regulates catabolic effects of continuous PTH on bone including monocyte and macrophage recruitment, osteoclast formation and bone resorption. In concer...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
AbstractProstate cancer is the most common cancer among men in the USA. Interestingly, recent studies suggest that patients with inflammatory bowel disease (IBD) are at increased risk of developing prostate cancer. Importantly, patients with IBD who develop prostate cancer require thoughtful care when using immunosuppressants to treat the IBD in the setting of malignancy. Further, consideration must be given to the proximity of the prostate to the gastrointestinal tract when treating with radiation where there is concern for the effects of inadvertent exposure of radiation to the diseased bowel. In general, management of i...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Nature Reviews Clinical Oncology, Published online: 11 November 2019; doi:10.1038/s41571-019-0284-3Systemic hormone therapies and chemotherapy are the cornerstones of treatment for patients with de novo metastatic prostate cancer, with a currently limited role for local treatments. Herein, the authors outline the pathobiological and immunological rationale for local cytoreductive treatment of the primary tumour and/or metastases in patients with this disease. They also review the preclinical and clinical evidence for the use of radical prostatectomy, prostate radiotherapy, minimally invasive ablative therapies, and metasta...
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 10 November 2019Source: European UrologyAuthor(s): Amar U. Kishan, Fang-I Chu, Christopher R. King, Wendy Seiferheld, Daniel E. Spratt, Phuoc Tran, Xiaoyan Wang, Stephanie E. Pugh, Kiri A. Sandler, Michel Bolla, Philippe Maingon, Theo De Reijke, Nicholas G. Nickols, Matthew Rettig, Alexandra Drakaki, Sandy T. Liu, Robert E. Reiter, Albert J. Chang, Felix Y. Feng, Dipti SajedAbstractBackgroundThe importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown.ObjectiveTo evaluate the clinical implications of LF after de...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Abstract Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: "Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and C...
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Tags: Curr Pharm Biotechnol Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Prostate Cancer | Urology & Nephrology